医疗与消费周观点：我国CDMO行业：核心优势突出，已迈入新阶段-20250618

Group 1 - The CDMO industry is a crucial partner for pharmaceutical companies, providing process development and production services. China has over 220 million talent resources, giving the CDMO industry a strong competitive edge [3][9]. - From 2018 to 2023, the Chinese CDMO market grew at a compound annual growth rate (CAGR) of 39.9%, increasing from 16 billion RMB to 85.9 billion RMB. It is projected to reach 208.4 billion RMB by 2028 and 536.9 billion RMB by 2033 [3][9][10]. - The industry is entering a new phase characterized by "technology deepening, global expansion, and ecological integration," but it faces challenges such as geopolitical issues, overcapacity, and technological disruption [10]. Group 2 - The report highlights that the medical and pharmaceutical sectors saw mixed performance, with six sub-industries showing varied returns. Medical devices and traditional Chinese medicine led the gains, while medical services and pharmaceutical commerce had lower increases [11]. - The report indicates that the valuation levels for the chemical pharmaceutical sector were the highest at 78.81 times, followed by biological products at 61.33 times, while traditional Chinese medicine and pharmaceutical commerce had lower valuations [11]. - The report emphasizes the increasing focus on early-stage projects in the CDMO industry, with 63.2% of financing events occurring in the A+ round or earlier, indicating a trend towards supporting emerging companies [10].